Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

IPTi in Mozambican Infants for Malaria Prevention

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Hospital Clinic of Barcelona.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier:
NCT00209794
First received: September 13, 2005
Last updated: November 15, 2006
Last verified: November 2006
  Purpose

To evaluate if intermittent preventive treatment in infants (IPTi) consisting of SP [Fansidar] given through the EPI scheme alongside routine immunisations at 3, 4 and 9 months of age reduces de incidence of clinical malaria up to 12 months of age


Condition Intervention Phase
Malaria
Drug: Sulfadoxine-Pyrimethamine (Fansidar)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: The Impact of Intermittent Malaria Treatment Administered Through the EPI Scheme on Malaria Morbidity in Mozambican Children

Resource links provided by NLM:


Further study details as provided by Hospital Clinic of Barcelona:

Primary Outcome Measures:
  • Incidence of first or only malaria episodes in each study cohort by 12 months of age.

Secondary Outcome Measures:
  • Incidence of first or only malaria episodes by group up to 12 months of age as per protocol analysis.
  • Incidence of first or only malaria episodes by group up to 24 months of age.
  • Incidence of multiple malaria episodes up to 12 months of age.
  • Incidence of multiple malaria episodes up to 24 months of age.
  • Incidence of overall and severe anaemia up to 12 months of age.
  • Incidence of overall and severe anaemia up to 24 months of age.
  • Proportion of humoral and cellular immune responses against malaria at 12 months of age.
  • Total number of admissions and outpatient attendances up to 24 months of age.
  • Prevalence of P falciparum parasitaemia and overall and severe anaemia at 12 months of age.
  • Proportion of humoral responses and geometric mean antibody titres of polio, DTP and Hepatitis B at 5 months and of measles at 9 and 12 months
  • Incidence of side effects in each group up to 12 months of age.

Estimated Enrollment: 1498
Study Start Date: September 2002
Estimated Study Completion Date: December 2005
Detailed Description:

The study is a randomised, double blind, placebo-controlled trial of the antimalarial drug sulphadoxine-pyrimethamine administered intermittently at 3, 4 and 9 months of age through the EPI scheme at the time of routine immunisations.

Children will be randomized into placebo and SP treatment groups by block randomization, and it is expected a similar age distribution and a similar number of children in each group.

Doses of sulphadoxine (25 mg/kg)-pyrimethamine (1.25 mg/kg) (SP) or placebo will be given by a health assistant according to bodyweight (a quarter of a tablet for those <5kg, a half for those 5-10 kg, and a whole tablet for children >10 kg). The tablets will be crashed and diluted with water for their administration.

  Eligibility

Ages Eligible for Study:   up to 3 Months
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Children from study area
  • Signed informed consent

Exclusion Criteria:

  • History of drug allergies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00209794

Locations
Mozambique
Centro de Investigaçao em Saude da Manhiça
Manhiça, Maputo, Mozambique
Sponsors and Collaborators
Hospital Clinic of Barcelona
Investigators
Principal Investigator: Clara Menendez, MD, PhD Center for International Health, Hospital Clinic de Barcelona
  More Information

Additional Information:
No publications provided by Hospital Clinic of Barcelona

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00209794     History of Changes
Other Study ID Numbers: TIM
Study First Received: September 13, 2005
Last Updated: November 15, 2006
Health Authority: Mozambique: Ministry of Health (MISAU)

Additional relevant MeSH terms:
Malaria
Parasitic Diseases
Protozoan Infections
Fanasil, pyrimethamine drug combination
Pyrimethamine
Sulfadoxine
Anti-Infective Agents
Anti-Infective Agents, Urinary
Antimalarials
Antiparasitic Agents
Antiprotozoal Agents
Enzyme Inhibitors
Folic Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Renal Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014